Analysts target $80.62 for CRSP, 40% above current levels, despite strong liquidity and an approved gene-editing therapy.
CRISPR Therapeutics holds $2.4 billion in cash and markets the healthcare industry’s first approved gene-editing therapy, yet its stock trades 40% below Wall Street’s $80.62 consensus target. The company’s sole approved treatment, priced at $2.2 million per patient, has seen over 500 users since late 2023 approval, signaling solid initial demand.
Despite a debt-light balance sheet and $5.5 billion market valuation, CRSP shares have stagnated since 2022. Analysts cite no single catalyst for the underperformance, though broader biotech sector pressures and high therapy costs may weigh on sentiment.
The company’s CRISPR/Cas9 gene-editing platform, co-developed by Nobel laureates, underpins its pipeline, but market skepticism persists despite fundamental strengths.